Glutathione creams have one measurable benefit in trials: a small, temporary drop in skin melanin. A 2025 systematic review found only five clinical trials of topical glutathione, each with 21 to 30 people, and the best of them lowered the melanin index by about 11% over 10 weeks. Claims about detox, anti-ageing or permanent whitening are not supported by any trial that we could find.
What does glutathione do in the skin?
Glutathione lowers the amount of dark pigment that skin cells make. It is a tripeptide, a small molecule built from three amino acids (glutamate, cysteine and glycine), and every cell in the body makes it to keep its internal chemistry in balance. The 2016 review by Sonthalia, Daulatabad and Sarkar in the Indian Journal of Dermatology, Venereology and Leprology (IJDVL) lists three ways it acts on pigment. It binds the copper site of tyrosinase, the enzyme that starts melanin production. It interferes with the transfer of tyrosinase into premelanosomes, the compartments where melanin is assembled. And it works indirectly as an antioxidant.
The IJDVL review adds a fourth effect: glutathione shifts melanin production from eumelanin, the brown-black pigment, towards phaeomelanin, the yellow-red pigment linked with lighter skin. The same review notes that glutathione affects only new melanin production, not pigment that is already in the skin, and that it acts mainly on sun-exposed areas.
The chemistry has a known gap. A 2018 review in Dermatology Practical & Conceptual (PMC5808366) reports cell studies in which plain glutathione did not inhibit tyrosinase or melanin production, while two modified (esterified) forms did. The authors say these results need further validation. A mechanism in a test tube is not the same as a cream that works on a face, which is why the trials below matter more than the biochemistry.
What benefits do glutathione creams claim?
Sellers claim skin whitening, fading of dark spots, anti-ageing, 'detox' and a glow; only the first two have been tested in people, and only briefly. The IJDVL review records that glutathione is sold in India as over-the-counter oral tablets, sublingual forms, soaps, face washes and creams, and that intravenous injections are promoted to reach 'therapeutic levels' in blood and skin. None of these product formats has an approved indication for skin lightening in India; the 2018 review (PMC5808366) states that CDSCO has approved intravenous glutathione only for alcoholic fatty liver, alcoholic liver fibrosis, alcoholic cirrhosis and alcoholic hepatitis.
The claims that have some trial support are narrow:
- A lower melanin index (an instrument reading of pigment) on treated skin after 8 to 10 weeks.
- A small change in wrinkle and moisture readings in one topical trial, reported in the 2025 systematic review (PMC12710870).
- In melasma, the 2025 Cureus review (PMC11862975) cites a 67.4% fall in a melasma severity score after 90 days of a 2% glutathione product.
The claims with no trial support are the broad ones. We found no trial of a glutathione cream for 'detox', for acne, for permanent whitening, or for lightening the whole body. The IJDVL review's conclusion is that there is 'a lack of robust evidence in favour of glutathione for the treatment of hyperpigmentation', and that the longevity of any lightening effect and the maintenance protocol are unanswered questions.
What do the trials of glutathione cream show?
The trials show a modest, measurable, short-lived lightening, in very small groups. The 2025 systematic review by Khanna, Rambhia and Chapas in the Journal of Clinical and Aesthetic Dermatology (PMC12710870) screened 446 records and found five clinical trials of topical glutathione, with 21 to 30 people each. Three of the five mixed glutathione with other actives, so their results cannot be credited to glutathione alone.
The cleanest trial is Watanabe's: a randomised, double-blind, placebo-controlled split-face study of 30 Filipino women aged 30 to 50 who applied 2% oxidised glutathione (GSSG) lotion twice daily for 10 weeks. The melanin index fell from 272.77 to 243.47, a drop of about 11%; one participant had mild redness that cleared by day 4. The 2018 review in Dermatology Practical & Conceptual describes the whitening as temporary.
| Trial (country) | People | Product | Result |
|---|---|---|---|
| Watanabe (Philippines) | 30 women | 2% GSSG lotion, 10 weeks | Melanin index 272.77 to 243.47 |
| Grandi (Italy) | 30 | 2% S-acyl glutathione cream | Minimal erythema dose 105 to 135 J/cm² |
| Jung (South Korea) | 24 women | 2% GSSG plus niacinamide, tranexamic acid | No adverse effects; mixed product |
| Cui (China) | 21 women | Glutathione blend | Dose not stated |
| Dall'Oglio (Italy) | 30 | 0.1% GSH-C4 plus azelaic acid | 10% discontinued; mixed product |
The review's authors say the trials had small samples, short follow-up and in some cases no control group, and that 'safety data is limited and warrants further exploration'.
Is cream, tablet or injection better for skin lightening?
No route has strong evidence, and the injectable route has the worst safety record. The 2018 review (PMC5808366) and the 2025 Cureus narrative review (PMC11862975) summarise the human studies by route.
Topical. The Watanabe trial above is the only randomised, placebo-controlled trial of glutathione alone on skin. Effect: about 11% fall in melanin index at 10 weeks, described as temporary.
Oral. Arjinpathana and Asawanonda gave 60 Thai medical students 500 mg/day for 4 weeks; the melanin index fell at all six sites, but differed from placebo at only two. Handog's open-label study of 30 women using a 500 mg lozenge for 8 weeks reported moderate lightening in 90%, with no placebo group. A 12-week randomised trial of 250 mg/day (PMC5413479) in 60 Thai women found melanin trends that were not statistically significant; two participants had temporary liver enzyme rises, and the manufacturer funded the trial.
Intravenous. Zubair's open-label study gave 50 Pakistani women 1,200 mg twice weekly for 6 weeks. Lightening was reported by 37.5% on glutathione versus 18.7% on placebo, faded to 6.2% versus 0% by six months, and 8 of 25 treated women (32%) developed liver dysfunction; one had anaphylactic shock.
| Route | Best evidence | Effect | Main concern |
|---|---|---|---|
| Cream or lotion | 1 RCT, 30 women | Small, temporary | Unknown long-term safety; hidden additives |
| Tablet or lozenge | 3 small trials | Inconsistent | Poor absorption; no standard dose |
| Injection | 1 open-label study, 50 women | Faded by 6 months | Liver dysfunction, anaphylaxis, infection |
How safe are glutathione creams?
Glutathione itself was well tolerated in the small topical trials; the danger comes from what else is in the tube and from injections. The 2025 systematic review (PMC12710870) recorded one case of mild, short-lived redness among 30 women in the Watanabe trial and no adverse effects in the 24-woman Korean trial, but it also states that safety data are limited. The 2025 Cureus review reports rare, mild local reactions for topical use, transient gut upset for oral use, and liver dysfunction and anaphylaxis for intravenous use.
The 2018 review (PMC5808366) lists the serious harms that have been reported with injectable glutathione: Stevens-Johnson syndrome and toxic epidermal necrolysis, severe abdominal pain, thyroid and kidney dysfunction, and air embolism and sepsis from unsterile injection or counterfeit product. The US FDA's 2019 compounding alert describes eight patients who reacted within minutes of compounded glutathione infusions, with nausea, vomiting, chills and in one case low blood pressure and breathing difficulty; the powder used carried the label 'Caution: Dietary Supplement' and FDA testing found bacterial endotoxin up to five times the limit.
Two HealthFinder guides cover safety in full. Glutathione cream uses and risks explains the hidden-steroid problem in Indian 'whitening' creams and what the CDSCO alerts name. Side effects of using glutathione cream lists the reactions by route and the signs that need a doctor.
See a dermatologist the same day if a cream causes blistering, peeling, swelling of the face or lips, or a rash that spreads; stop the product and bring the tube with you.
What do CDSCO and the FDA say about glutathione products?
Neither regulator approves any glutathione product for skin lightening. In India, the Central Drugs Standard Control Organisation (CDSCO) issued a public notice on 18 May 2026 that quotes the definition of a cosmetic in the Drugs and Cosmetics Act, 1940, and states that 'products supplied in form of injectable preparation do not fall under the definition of cosmetics' and that 'no cosmetic is permitted to be used as injection by consumer/ professionals/ aesthetic clinics'. The notice adds that no cosmetic may be used in treatment, that misleading label claims are a violation, and that the public can report breaches to cosmetics@cdsco.nic.in or the State Licensing Authority. A glutathione cream sold legally in India is therefore a cosmetic: it may claim to beautify, not to treat.
The 2018 review (PMC5808366) records that CDSCO has approved intravenous glutathione only for alcoholic liver disease, and the IJDVL review notes that oral glutathione has become available over the counter in India without a standardised dose.
In the United States, the FDA's drug safety communication of April 2022 states that 'there are no FDA-approved or otherwise legally marketed OTC skin lightening products', and that every such product needs an approved new drug application. Its only approved hydroquinone product is a prescription treatment for melasma. A separate FDA consumer update on injectable skin-lightening products, which names glutathione, vitamin C, collagen and human placenta as ingredients, says the FDA has approved no injectable for skin whitening and that these are unapproved new drugs with unknown ingredients and infection risk.
Who should see a dermatologist instead of buying a cream?
Anyone with a pigment problem that has a name, such as melasma, post-inflammatory marks or a patch that is changing, should see a dermatologist before spending on glutathione. The IJDVL review states that ultraviolet exposure is the most important cause of unwanted pigmentation and that glutathione affects only new melanin, so a cream without daily sun protection is working against the main driver. A dermatologist can diagnose the type of pigmentation, prescribe treatments that have larger trials behind them, and check that no steroid or mercury is hidden in a product you are already using.
Use these points when you weigh a glutathione cream:
- The measured benefit is about an 11% fall in melanin index after 10 weeks, in one trial of 30 women, and it was temporary.
- No trial has run for longer than a few months, so nobody knows the long-term effect of daily use.
- A legal cream in India is a cosmetic; a product that claims to 'treat' pigmentation or is offered as a drip is outside the law under CDSCO's 18 May 2026 notice.
- The 2025 systematic review asks for larger randomised trials and raises the ethics of selling glutathione as a bleaching agent.
If months of a 'whitening' cream have left thinning skin, visible veins, acne or redness that flares when you stop, that pattern points to a hidden steroid, not glutathione; the guide on uses and risks explains what to do. This guide is general information from the sources listed below, not medical advice; a registered doctor makes decisions with you.
